UK Life Sciences Sector Attracts £3 Billion Investment to Boost Jobs and Healthcare

UK Reports £3 Billion Boost for Life Sciences, Supporting Jobs and Faster Patient Care

July, 2026 : The United Kingdom’s life sciences sector has attracted more than £3 billion in new public and private investment over the past year, marking significant progress under the government’s Life Sciences Sector Plan and reinforcing confidence in the country’s research, innovation and healthcare capabilities.

According to the UK government, the investment has helped accelerate the development of new medicines, reduce clinical trial approval times and support economic growth through high-value jobs across the country.

The first annual update on the Life Sciences Sector Plan, released on 9 July, outlines progress made during its first year and highlights the government’s ambition to position the UK as the world’s third-largest life sciences economy by 2035.

One of the major outcomes has been improved access to innovative treatments for patients. The report notes that the world’s first immunotherapy treatment for type 1 diabetes was approved for use by the NHS in England and Wales last month, providing patients with access to a new generation of therapies.

Why is the UK investing more than £3 billion in the life sciences sector?
The investment is designed to strengthen the UK’s life sciences industry by supporting scientific research, attracting global investment, accelerating innovation, improving healthcare outcomes and creating high-skilled jobs. The government’s long-term ambition is to make the UK the world’s third-largest life sciences economy by 2035

Clinical research has also become more efficient. Average clinical trial set-up times have fallen from 169 days to 122 days during the first half of the 2025-2026 period, surpassing the government’s target of reducing approvals to under 150 days. In addition, patients are expected to receive access to new medicines up to six months earlier through the joint approval process introduced by the Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE).

The government said the sector continues to play a major role in the national economy, generating around £147 billion in annual turnover while supporting approximately 360,000 jobs across the UK. Nearly half of those roles are located outside London, the East and South East of England, highlighting the sector’s contribution to regional economic development.

Alongside healthcare improvements, several major private sector investments have strengthened the UK’s research and manufacturing capabilities.

Among the largest commitments, AstraZeneca announced a £300 million investment to expand operations at its Cambridge headquarters and a facility in Macclesfield focused on using artificial intelligence to accelerate drug discovery. Moderna has opened its innovation centre in Harwell as part of its £1 billion research and development commitment in the UK over the next decade, while UCB is investing £500 million in a new research and development hub in Windlesham, Surrey, dedicated to developing medicines for immunological diseases.

To support long-term industry growth, the government has also introduced a dedicated Life Sciences Sector Jobs Plan, aimed at helping the sector fill an estimated 66,000 additional roles by 2035.

The initiative focuses on priority occupations including laboratory technicians, chemical scientists and software developers. It also seeks to strengthen apprenticeship pathways, expand technical education through qualifications such as T Levels and future V Levels, and encourage lifelong learning through Skills Bootcamps and the Lifelong Learning Entitlement. The strategy is designed to prepare the workforce for emerging technologies including artificial intelligence and quantum computing.

A new industry-led life sciences skills body will also be established to bring together government, employers, trade unions and training providers to identify workforce shortages and provide advice on future skills development.

The update also confirms the formal incorporation of the Health Data Research Service (HDRS) as a company, moving the programme from planning into delivery. The service is intended to simplify secure access to health data for approved researchers, enabling faster scientific discoveries while supporting improvements in patient care.

The government said the Life Sciences Sector Plan has been developed alongside the Modern Industrial Strategy and the NHS 10 Year Health Plan, with the aim of strengthening the UK’s position as a global centre for science, innovation and advanced healthcare.

What new jobs will be created and who could benefit?
The government’s new Life Sciences Sector Jobs Plan aims to help support around 66,000 additional roles by 2035. Opportunities are expected across laboratory science, chemical research, software development, manufacturing, data science and other technical professions, supported by apprenticeships, technical education and workforce training programmes.

Government-backed funding has also continued to attract private investment. The £520 million Life Sciences Innovative Manufacturing Fund has generated more than £700 million in additional investment over the past 12 months while creating or safeguarding more than 1,300 jobs, according to the update.

The government also highlighted efforts to strengthen pharmaceutical collaboration with the United States through a UK-US pharmaceutical arrangement. Officials said the agreement supports continued access to innovative medicines for NHS patients while securing a commitment to zero tariffs on UK pharmaceutical exports to the US.

The latest progress report indicates that the government intends to continue expanding investment, developing a skilled workforce and accelerating medical innovation as part of its long-term strategy to strengthen both the UK’s economy and healthcare system.

Key Points

UK life sciences sector attracted more than £3 billion in new public and private investment over the past year.
Clinical trial set-up times fell from 169 days to 122 days, exceeding the government’s target.
Patients are expected to gain access to new medicines up to six months earlier through the joint MHRA-NICE approval process.
The sector generates around £147 billion annually and supports approximately 360,000 jobs across the UK.
A new Jobs Plan aims to help fill 66,000 additional life sciences roles by 2035.
AstraZeneca, Moderna and UCB announced major investments supporting UK research and manufacturing.
The Health Data Research Service has formally moved into its delivery phase to improve secure research access to health data.
The £520 million Life Sciences Innovative Manufacturing Fund has attracted more than £700 million in additional investment while creating or protecting over 1,300 jobs.

Editorial Note: This article is intended for informational and educational purposes only. It provides analytical insights based on publicly available information and does not constitute financial, legal, or political advice. Readers are encouraged to consult official sources and expert advisors for verified guidance.